Sökning: onr:"swepub:oai:DiVA.org:uu-381085" >
Cytogenetic complex...
Cytogenetic complexity in chronic lymphocytic leukemia : definitions, associations, and clinical impact
-
- Baliakas, Panagiotis, 1977- (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi
-
- Jeromin, Sabine (författare)
- Munich Leukemia Lab, Munich, Germany
-
- Iskas, Michalis (författare)
- G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece
-
visa fler...
-
- Puiggros, Anna (författare)
- Hosp del Mar, Serv Patol, Lab Citogenet Mol, Barcelona, Spain;Inst Hosp del Mar Invest Med IMIM, Programa Recerca Canc, Grp Recerca Translac Neoplasies Hematol, Barcelona, Spain
-
- Plevova, Karla (författare)
- Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic;Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic;Masaryk Univ, Fac Med, Brno, Czech Republic
-
- Nguyen-Khac, Florence (författare)
- Hematol Dept, Paris, France;Sorbonne Univ, Hop Pitie Salpetriere, INSERM, U1138, Paris, France
-
- Davis, Zadie (författare)
- Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England
-
- Rigolin, Gian Matteo (författare)
- St Anna Univ Hosp, Hematol Sect, Ferrara, Italy
-
- Visentin, Andrea (författare)
- Univ Padua, Dept Med, Hematol Div, Padua, Italy
-
- Xochelli, Aliki (författare)
- Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki 57001, Greece
-
- Delgado, Julio (författare)
- Univ Barcelona, Hosp Clin, Dept Hematol, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
-
- Baran-Marszak, Fanny (författare)
- Hop Avicenne, Assistance Publ Hop Paris, Lab Hematol, Paris, France
-
- Stalika, Evangelia (författare)
- Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki 57001, Greece
-
- Abrisqueta, Pau (författare)
- Hosp Valle De Hebron, Serv Hematol, Barcelona, Spain
-
- Durechova, Kristina (författare)
- Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic;Masaryk Univ, Fac Med, Brno, Czech Republic
-
- Papaioannou, George (författare)
- G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece
-
- Eclache, Virginie (författare)
- Hop Avicenne, Assistance Publ Hop Paris, Lab Hematol, Paris, France
-
- Dimou, Maria (författare)
- Univ Athens, Laikon Univ Hosp, Dept Propedeut Internal Med 1, Hematol Sect, Athens, Greece
-
- Iliakis, Theodoros (författare)
- Univ Athens, Laikon Univ Hosp, Dept Propedeut Internal Med 1, Hematol Sect, Athens, Greece
-
- Collado, Rosa (författare)
- Consorcio Hosp Gen Univ, Serv Hematol, Valencia, Spain
-
- Doubek, Michael (författare)
- Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic;Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic;Masaryk Univ, Fac Med, Brno, Czech Republic
-
- Jose Calasanz, M. (författare)
- Univ Navarra, Dept Genet, Serv Genet Citogenet, Pamplona, Spain
-
- Ruiz-Xiville, Neus (författare)
- Univ Autonoma Barcelona, Inst Recerca Leucemia Josep Carreras IJC, ICO Hosp Germans Trias & Pujol, Serv Lab Hematol, Badalona, Spain
-
- Moreno, Carolina (författare)
- Hosp Univ Santa Creu & St Pau, Serv Hematol, Barcelona, Spain
-
- Jarosova, Marie (författare)
- Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic;Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic;Masaryk Univ, Fac Med, Brno, Czech Republic
-
- Leeksma, Alexander C. (författare)
- Univ Amsterdam, Acad Med Ctr Amsterdam, Dept Hematol & Lymphoma, Amsterdam, Netherlands;Univ Amsterdam, Acad Med Ctr Amsterdam, Myeloma Ctr Amsterdam, Amsterdam, Netherlands;Canc Ctr Amsterdam, Dept Expt Immunol, Amsterdam, Netherlands;Infect & Immun Inst Amsterdam, Amsterdam, Netherlands
-
- Panayiotidis, Panayiotis (författare)
- Univ Athens, Laikon Univ Hosp, Dept Propedeut Internal Med 1, Hematol Sect, Athens, Greece
-
- Podgornik, Helena (författare)
- Univ Med Ctr Ljubljana, Dept Hematol, Ljubljana, Slovenia
-
- Cymbalista, Florence (författare)
- Hop Avicenne, Assistance Publ Hop Paris, Lab Hematol, Paris, France
-
- Anagnostopoulos, Achilles (författare)
- G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece
-
- Trentin, Livio (författare)
- Univ Padua, Dept Med, Hematol Div, Padua, Italy
-
- Stavroyianni, Niki (författare)
- G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece
-
- Davi, Fred (författare)
- Hematol Dept, Paris, France;Sorbonne Univ, Hop Pitie Salpetriere, INSERM, U1138, Paris, France
-
- Ghia, Paolo (författare)
- IRCCS San Raffaele Sci Inst, Div Expt Oncol, Strateg Res Program CLL, Milan, Italy;Univ Vita Salute San Raffaele, Milan, Italy
-
- Kater, Arnon P. (författare)
- Univ Amsterdam, Acad Med Ctr Amsterdam, Dept Hematol & Lymphoma, Amsterdam, Netherlands;Univ Amsterdam, Acad Med Ctr Amsterdam, Myeloma Ctr Amsterdam, Amsterdam, Netherlands;Canc Ctr Amsterdam, Dept Expt Immunol, Amsterdam, Netherlands;Infect & Immun Inst Amsterdam, Amsterdam, Netherlands
-
- Cuneo, Antonio (författare)
- St Anna Univ Hosp, Hematol Sect, Ferrara, Italy
-
- Pospisilova, Sarka (författare)
- Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic;Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic;Masaryk Univ, Fac Med, Brno, Czech Republic
-
- Espinet, Blanca (författare)
- Hosp del Mar, Serv Patol, Lab Citogenet Mol, Barcelona, Spain;Inst Hosp del Mar Invest Med IMIM, Programa Recerca Canc, Grp Recerca Translac Neoplasies Hematol, Barcelona, Spain
-
- Athanasiadou, Anastasia (författare)
- G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece
-
- Oscier, David (författare)
- Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England
-
- Haferlach, Claudia (författare)
- Munich Leukemia Lab, Munich, Germany
-
- Stamatopoulos, Kostas (författare)
- Uppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab,Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki 57001, Greece
-
visa färre...
-
(creator_code:org_t)
- American Society of Hematology, 2019
- 2019
- Engelska.
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 133:11, s. 1205-1216
- Relaterad länk:
-
https://ashpublicati...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Recent evidence suggests that complex karyotype (CK) defined by the presence of >= 3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with >= 5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage, TP53 aberrations (deletion of chromosome 17p and/or TP53 mutations [TP53abs]), and the expression of somatically hypermutated (M-CLL) or unmutated immunoglobulin heavy variable genes. Thus, they contrasted with CK cases with 3 or 4 aberrations (low-CK and intermediate-CK, respectively) who followed aggressive disease courses only in the presence of TP53abs. At the other end of the spectrum, patients with CK and 112,119 displayed an exceptionally indolent profile. Building upon CK, TP53abs, and immunoglobulin heavy variable gene somatic hyper-mutation status, we propose a novel hierarchical model in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with 112,119, show the longest overall survival. Thus, CK should not be axiomatically considered unfavorable in CLL, representing a heterogeneous group with variable clinical behavior. High-CK with >= 5 chromosomal aberrations emerges as prognostically adverse, independent of other biomarkers. Prospective clinical validation is warranted before ultimately incorporating high-CK in risk stratification of CLL.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Blood
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Baliakas, Panagi ...
-
Jeromin, Sabine
-
Iskas, Michalis
-
Puiggros, Anna
-
Plevova, Karla
-
Nguyen-Khac, Flo ...
-
visa fler...
-
Davis, Zadie
-
Rigolin, Gian Ma ...
-
Visentin, Andrea
-
Xochelli, Aliki
-
Delgado, Julio
-
Baran-Marszak, F ...
-
Stalika, Evangel ...
-
Abrisqueta, Pau
-
Durechova, Krist ...
-
Papaioannou, Geo ...
-
Eclache, Virgini ...
-
Dimou, Maria
-
Iliakis, Theodor ...
-
Collado, Rosa
-
Doubek, Michael
-
Jose Calasanz, M ...
-
Ruiz-Xiville, Ne ...
-
Moreno, Carolina
-
Jarosova, Marie
-
Leeksma, Alexand ...
-
Panayiotidis, Pa ...
-
Podgornik, Helen ...
-
Cymbalista, Flor ...
-
Anagnostopoulos, ...
-
Trentin, Livio
-
Stavroyianni, Ni ...
-
Davi, Fred
-
Ghia, Paolo
-
Kater, Arnon P.
-
Cuneo, Antonio
-
Pospisilova, Sar ...
-
Espinet, Blanca
-
Athanasiadou, An ...
-
Oscier, David
-
Haferlach, Claud ...
-
Stamatopoulos, K ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Blood
- Av lärosätet
-
Uppsala universitet